You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Harvard Business School
Mallinckrodt
McKesson
Colorcon
Medtronic
Express Scripts

Last Updated: September 28, 2020

DrugPatentWatch Database Preview

Patent: 9,890,429

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,890,429
Title:Compositions, kits, and methods for the identification, assessment, prevention, and therapy of cancer
Abstract: The present invention relates to compositions, kits, and methods for detecting, characterizing, preventing, and treating cancer (e.g., hematological malignancies in humans). A variety of biomarker chromosomal number alterations (CNAs) and biomarkers corresponding thereto, are provided, wherein alterations in the copy number of one or more of the biomarker CNAs and/or alterations in the amount, structure, and/or activity of one or more of the biomarkers comprised within the CNAs is associated with cancer status.
Inventor(s): Shipp; Margaret A. (Wellesley, MA), Monti; Stefano (Somerville, MA), Chapuy; Bjoern (Boston, MA), Rodig; Scott J. (Westwood, MA), Golub; Todd R. (Newton, MA)
Assignee: Dana-Farber Cancer Institute, Inc. (Boston, MA) The Broad Institute, Inc. (Cambridge, MA)
Application Number:14/381,004
Patent Claims:see list of patent claims

Details for Patent 9,890,429

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 001 1997-11-26   Start Trial Dana-Farber Cancer Institute, Inc. (Boston, MA) The Broad Institute, Inc. (Cambridge, MA) 2032-02-29 RX search
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 002 1997-11-26   Start Trial Dana-Farber Cancer Institute, Inc. (Boston, MA) The Broad Institute, Inc. (Cambridge, MA) 2032-02-29 RX search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 001 2017-06-22   Start Trial Dana-Farber Cancer Institute, Inc. (Boston, MA) The Broad Institute, Inc. (Cambridge, MA) 2032-02-29 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Johnson and Johnson
Boehringer Ingelheim
Mallinckrodt
Merck
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.